Van Tine, B. A., Ingham, M. A., Attia, S., Meyer, C. F., Baird, J. D., Brooks-Asplund, E., D’Silva, D., Kong, R., Mwatha, A., O’Keefe, K., Weetall, M., Spiegel, R., & Schwartz, G. K. (2024). Phase Ib Study of Unesbulin (PTC596) Plus Dacarbazine for the Treatment of Locally Recurrent, Unresectable or Metastatic, Relapsed or Refractory Leiomyosarcoma. Journal of Clinical Oncology, 42(20), 2404–2414. https://doi.org/10.1200/jco.23.01684

Ingham, M., Allred, J. B., Chen, L., Das, B., Kochupurakkal, B., Gano, K., George, S., Attia, S., Burgess, M. A., Seetharam, M., Boikos, S. A., Bui, N., Chen, J. L., Close, J. L., Cote, G. M., Thaker, P. H., Ivy, S. P., Bose, S., D’Andrea, A., … Schwartz, G. K. (2023). Phase II Study of Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma (NCI Protocol 10250). Journal of Clinical Oncology, 41(25), 4154–4163. https://doi.org/10.1200/jco.23.00402

Diggs, A., Sia, T. Y., Huang, Y., Gockley, A., Melamed, A., Khoury-Collado, F., St. Clair, C., Hou, J. Y., Hershman, D. L., & Wright, J. D. (2022). Utilization and outcomes of adjuvant therapy for stage II and III uterine leiomyosarcoma. Gynecologic Oncology, 166(2), 308–316. https://doi.org/10.1016/j.ygyno.2022.05.018

Bose, S., Schwartz, G. K., & Ingham, M. (2022). Novel Therapeutics in the Treatment of Uterine Sarcoma. American Society of Clinical Oncology Educational Book, 42, 900–909. https://doi.org/10.1200/edbk_350541

Kasper, B., D’Ambrosio, L., Davis, E. J., Ingham, M., Broto, J. M., Trent, J. C., van Houdt, W. J., & Van Tine, B. A. (2022). What Clinical Trials Are Needed for Treatment of Leiomyosarcoma? Current Treatment Options in Oncology, 23(3), 439–449. https://doi.org/10.1007/s11864-021-00928-y